Ultomiris approval gives AstraZeneca’s Alexion Rare Disease division a U.S. indication to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN. AstraZeneca announced the FDA decision on October 21, 2026, while the treatment’s ability to slow kidney function decline remains under investigation.
Key Takeaways
- The FDA approved Ultomiris, also known as ravulizumab, to reduce proteinuria in adults with primary IgAN.
- An interim analysis showed a 43.4% reduction in proteinuria compared with placebo after 34 weeks.
- The ongoing I CAN Phase III trial is still investigating whether the drug slows kidney function decline.
Table of Contents
Ultomiris approval rests on proteinuria results
In an interim analysis, Ultomiris reduced proteinuria, a surrogate marker for kidney disease progression, by 43.4% compared with placebo after 34 weeks.
The distinction between that result and longer-term kidney outcomes is important: the reported approval covers proteinuria reduction, not an established ability to slow the decline in kidney function. That question remains part of the ongoing I CAN Phase III trial.
Primary IgAN puts patients at risk of worsening kidney disease. The new indication allows Alexion to address adults with the condition while the trial continues.
AstraZeneca’s financial snapshot
The decision concerns AstraZeneca’s rare-disease portfolio, which includes the complement-inhibitor medicines Soliris and Ultomiris. The company also operates across oncology, cardiovascular, renal, metabolic, respiratory and immunology treatments.
AstraZeneca’s quoted share price was $168.45, with a market capitalization of $262.11 billion.
AstraZeneca’s dividend yield was 1.76%, its payout ratio was 16% and its three-year dividend growth rate was minus 0.4%.
Conclusion
The FDA decision establishes a proteinuria-reduction indication for Ultomiris in adults with primary IgAN. Whether that benefit translates into slower kidney function decline remains an open question in the continuing Phase III trial.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
